NCT00459043 - Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

February 29, 2012

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

ZD6474

Taken orally once every morning

DRUG

Docetaxel

Given on the first day of every treatment cycle (every 3 weeks)

Trial Locations (3)

Loyola University Medical Center/Cardinal Bernadin Cancer Center, Maywood

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston